Premium
Andrographolide regulates epidermal growth factor receptor and transferrin receptor trafficking in epidermoid carcinoma (A‐431) cells
Author(s) -
Tan Y,
Chiow KH,
Huang D,
Wong SH
Publication year - 2010
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/j.1476-5381.2009.00627.x
Subject(s) - andrographolide , transferrin receptor , endosome , receptor , epidermal growth factor receptor , microbiology and biotechnology , cancer cell , biology , andrographis paniculata , cancer research , growth factor receptor , programmed cell death , apoptosis , signal transduction , cancer , pharmacology , medicine , biochemistry , pathology , genetics , alternative medicine
Background and purpose: Andrographolide is the active component of Andrographis paniculata , a plant used in both Indian and Chinese traditional medicine, and it has been demonstrated to induce apoptosis in different cancer cell lines. However, not much is known about how it may affect the key receptors implicated in cancer. Knowledge of how andrographolide affects receptor trafficking will allow us to better understand new mechanisms by which andrographolide may cause death in cancer cells. Experimental approach: We utilized the well‐characterized epidermal growth factor receptor (EGFR) and transferrin receptor (TfR) expressed in epidermoid carcinoma (A‐431) cells as a model to study the effect of andrographolide on receptor trafficking. Receptor distribution, the total number of receptors and surface receptors were analysed by immunofluorescence, Western blot as well as flow‐cytometry respectively. Key results: Andrographolide treatment inhibited cell growth, down‐regulated EGFRs on the cell surface and affected the degradation of EGFRs and TfRs. The EGFR was internalized into the cell at an increased rate, and accumulated in a compartment that co‐localizes with the lysosomal‐associated membrane protein in the late endosomes. Conclusion and implications: This study sheds light on how andrographolide may affect receptor trafficking by inhibiting receptor movement from the late endosomes to lysosomes. The down‐regulation of EGFR from the cell surface also indicates a new mechanism by which andrographolide may induce cancer cell death.